Novel Small Molecule Inhibitors of GSL-1 as Potential Agents for the Treatment of Metabolic Disorders
Abstract Small molecule inhibitors of glutaminase (GSL1) are described as potential treatment of metabolic diseases including obesity, diabetes, liver diseases, muscular atrophy and atherosclerosis. Glutaminolysis is an alternative to glycosis as a source of carbon for energy homeostasis and is a major source of energy in the brain and other organs. Glutaminase (GSL1) is a mitochondrial enzyme converting glutamine into glutamate through glutaminolysis. Excessive glutaminolysis is associated with accelerated aging.
Authors
- Gérard Rossé (ORCID: https://orcid.org/0000-0003-1993-3575)
Institutions
- World Trade Organization (CH)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1021/acsmedchemlett.6c00581
- Primary Topic
- Amino Acid Enzymes and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00